TGFB1 and neoplasm: Our model allows for the possibility that new therapeutic strategies can be developed against TGF-β1 signalling components and/or TGF-β1 target genes to slow the development of metastatic tumours by specifically inhibiting steps in the extravasation and dissemination of CTC clusters.